Arcturus Therapeutics Holdings Inc (ARCT NASDAQ) stock market data APIs
$13.7641
-0.03(-0.2%)
as of July 3, 2025
Try our APIs with
free plan!
Arcturus Therapeutics Holdings Inc Financial Data Overview
Price chart is built with
Anychart
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Prev. Close
13.7641
Open
13.7365
High
13.8647
Low
13.4516
52 wk Range
8.04-25.88
Market Cap
374 M
Shares Outstanding
27 121 K
Revenue
144 M
EPS
-0.52
Beta
2.291
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Arcturus Therapeutics Holdings Inc data using free add-ons & libraries
Get Arcturus Therapeutics Holdings Inc Fundamental Data
Arcturus Therapeutics Holdings Inc Fundamental data includes:
- Net Revenue: 144 M
- EBITDA: -78 642 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-13
- EPS/Forecast: -1.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arcturus Therapeutics Holdings Inc News
New
Arcturus reports positive phase 2 results for OTC deficiency therapy
SAN DIEGO - Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a $375 million market cap biotech company whose stock has seen a -21% return year-to-date, announced positive interim results from Phase ...
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA...
Vaccine Stocks Surge: Moderna Jumps 11% as COVID-19 and Flu Fears Reignite Immunization Demand
Tuesday saw bumps in Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for immunization-or...
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
